Treatment of Opioid Use Disorders in Jails and Prisons Why, When, and How
|
|
|
- Milo Godfrey Alexander
- 8 years ago
- Views:
Transcription
1 Treatment of Opioid Use Disorders in Jails and Prisons Why, When, and How Kevin Fiscella, MD, MPH Professor, Family Medicine, Public Health Sciences, Community Health University of Rochester School of Medicine & Dentistry
2 Medical detoxification is considered the standard of care for individuals with opiate dependence. Opiate withdrawal is rarely dangerous except in medically debilitated individuals and pregnant women.
3 Medical detoxification is considered the standard of care for individuals with opiate dependence. Opiate withdrawal is rarely dangerous except in medically debilitated individuals and pregnant women. -Federal Bureau of Prisons Clinical Practice Guidelines February 2014
4 Medical detoxification is considered the standard of care for individuals with opiate dependence. Opiate withdrawal is rarely dangerous except in medically debilitated individuals and pregnant women. -Federal Bureau of Prisons Clinical Practice Guidelines February 2014
5 Jail Detox Tragic endings
6 Jail Detox Tragic endings Last May, a 25-year old male heroin user turned himself into the county jail last after telling his parents he was afraid to detox in jail. His parents hoping for tough love declined to post bail. He was transferred to the jail medical unit. He received a standard jail opioid withdrawal protocol: regular vital signs checks, Gatorade, clonidine, hydroxyzine, acetaminophen, Pepto- Bismol, loperamide, and promethazine. Three days later, he was dead. Following discussion with the forensic pathologist and review of medical records, the DA concluded: All the evidence indicates that Mr. Tabor died as a natural result of heroin withdrawal.
7 Why?
8 Treatment of opioid use disorders in jails and prisons is too often substandard
9 Treatment of opioid use disorders in jails and prisons is too often substandard Opioid agonist treatment is routinely abruptly stopped following arrest (before conviction).
10 Treatment of opioid use disorders in jails and prisons is too often substandard Opioid agonist treatment is routinely stopped Opioid agonists are infrequently used to detoxify patients regardless of the severity of withdrawal.
11 Treatment of opioid use disorders in jails and prisons is too often substandard Opioid agonist treatment is routinely stopped Opioid agonists are infrequently used to detoxify patients regardless of severity of withdrawal Opioid treatment is generally not initiated prior to release.
12 Treatment of opioid use disorders in jails and prisons is too often substandard Opioid agonist treatment is routinely stopped Opioid agonists are infrequently used to detoxify patients regardless of severity of withdrawal Opioid treatment is not initiated prior to release Patients are not routinely referred to opioid treatment programs prior to release.
13 Why is reform needed?
14 Why is reform needed? Treatment for opioid disorders in corrections is generally not evidenced-based.
15 Why is reform needed?
16 Why is reform needed? Poor treatment is bad medicine Poor treatment is inhumane.
17 Why is reform needed? THE LANCET July 2015
18 Why is reform needed? Poor treatment is bad medicine Poor treatment is inhuman Poor treatment perpetuates stigma around opioid use disorders.
19 Why is reform needed? Poor treatment is bad medicine Poor treatment is inhuman Poor treatment perpetuates myths Poor treatment represents a missed opportunity to halt the opioid epidemic by engaging patient in evidence-based treatment.
20 Why is reform needed? JAM A January 14, 2009-Vol 301, No. 2
21 Why is reform needed? JAM A January 14, 2009-Vol 301, No. 2
22 Why is reform needed? Despite increasing evidence that addiction is a treatable disease of the brain, most individuals do not receive treatment. Involvement in the criminal justice system often results from illegal drug-seeking behavior and participation in illegal activities that reflect, in part, disrupted behavior ensuing from brain changes triggered by repeated drug use. Treating drug-involved offenders provides a unique opportunity to decrease substance abuse and reduce associated criminal behavior. Emerging neuroscience has the potential to transform traditional sanction-oriented public safety approaches by providing new therapeutic strategies against addiction that could be used in the criminal justice system. -Chandler et al, JAMA, 2009
23 ASAM and NCCHC recommend reform
24 ASAM National Practice Guideline Summary of Recommendations
25 ASAM National Practice Guideline Summary of Recommendations 1. Pharmacotherapy, has been shown to be effective and is recommended for prisoners and parolees regardless of the length of their sentenced term.
26 ASAM National Practice Guideline Summary of Recommendations 1. Pharmacotherapy, has been shown to be effective and is recommended for prisoners and parolees regardless of the length of their sentenced term. 2. Individuals with opioid use disorder who are within the criminal justice system should be treated with some type of pharmacotherapy in addition to psychosocial treatment.
27 ASAM National Practice Guideline Summary of Recommendations 3. Opioid agonists (methadone and buprenorphine) and antagonists (naltrexone) may be considered for treatment. There is insufficient evidence to recommend any one treatment as superior to another for prisoners or parolees.
28 THE LANCET July 2015
29
30 ASAM National Practice Guideline Summary of Recommendations 3. Opioid agonists (methadone and buprenorphine) and antagonists (naltrexone) may be considered for treatment. There is insufficient evidence to recommend any one treatment as superior to another for prisoners or parolees. 3. Pharmacotherapy should be initiated a minimum of 30 days before release from prison.
31 NCCHC Recommendations
32 NCCHC Recommendations 1. Screen detainees/inmates upon entry using valid instruments
33 NCCHC Recommendations 1. Screening of detainees/inmates upon entry using valid instruments that are available from a variety of sources. 2. Assure that correctional and health staff receive appropriate training screening.
34 NCCHC Recommendations 1. Screening of detainees/inmates upon entry using valid instruments that are available from a variety of sources. 2. Assuring that correctional and health staff receive appropriate training in receiving screening. 3. Provide formal evaluation for substance use disorders and comorbidity, including concurrent mental health disorders, by qualified health professionals trained and experienced in managing comorbid disorders.
35 NCCHC Recommendations 1. Screening of detainees/inmates upon entry using valid instruments that are available from a variety of sources. 2. Assuring that correctional and health staff receive appropriate training in receiving screening. 3. Formal evaluation for substance use disorder and comorbidity, including concurrent mental health disorders, by qualified health professionals trained and experienced in managing comorbid disorders. 4. If ordered by a correctional physician, continue prescribed medications for substance use disorders.
36 NCCHC Recommendations 5. Assess opioid and alcohol/sedative withdrawal using valid withdrawal scales.
37 NCCHC Recommendations 5. Assessment of opioid and alcohol/sedative withdrawal using valid scales such as the Alcohol Withdrawal Assessment Scoring Guidelines (CIWA-Ar) and the Clinical Opiate Withdrawal Scale (COWS). 6. Provide evidence-based treatment such as cognitivebehavioral treatment and medication-assisted treatment of substance withdrawal.
38 NCCHC Recommendations 5. Assessment of opioid and alcohol/sedative withdrawal using valid scales such as the Alcohol Withdrawal Assessment Scoring Guidelines (CIWA-Ar) and the Clinical Opiate Withdrawal Scale (COWS). 6. Evidence-based treatment such as cognitive-behavioral treatment and medication-assisted treatment of substance withdrawal. 7. Provide evidence-based behavioral and pharmacological treatment for substance use and mental health disorders.
39 NCCHC Recommendations 5. Assessment of opioid and alcohol/sedative withdrawal using valid scales such as the Alcohol Withdrawal Assessment Scoring Guidelines (CIWA-Ar) and the Clinical Opiate Withdrawal Scale (COWS). 6. Evidence-based treatment such as cognitive-behavioral treatment and medication-assisted treatment of substance withdrawal. 7. Evidence-based behavioral and pharmacological treatment for substance use and mental health disorders. 8. Provide prerelease referral for, and coordination of, treatment for substance use and mental health disorders.
40 Why Not?
41 Correctional health care is marginalized
42 Limited regulatory oversight
43 Correctional culture
44 Bias against medication-assisted treatment
45 Bias against medication-assisted treatment
46 Lack of funding for health care $ services in jails and prisons $
47 Poor exchange of health information
48 Poor exchange of health information
49 Poor exchange of health information
50 Poor exchange of health information
51
52 DEA
53 DEA
54 When?
55 When to treat?
56 When to treat? Continue existing agonist treatment among people arrested and detained.
57 When to treat? Continue existing treatment among people arrested and detained Use opioid agonists for detoxification.
58 When to treat? Continue existing treatment among people arrested and detained Use of opioid agonists for detoxification Initiate opioid agonists prior to release.
59 How?
60 How to do it?
61 How to do it? 1. Jails and prisons can partner with community opioid treatment programs to dose inmates in jail or prison.
62 How to do it? 1. Jails and prisons can partner with community opioid treatment programs to dose inmates 2. Physicians working in jails and prisons can obtain a license to prescribe buprenorphine.
63 How to do it? 1. Jails and prisons can partner with community opioid treatment programs to dose inmates 2. Physicians working in jails and prisons can obtain a license to prescribe buprenorphine 3. Jails and prisons can obtain a facility license as an opioid treatment program.
64 How to do it? 1. Jails and prisons can partner with community opioid treatment programs to dose inmates 2. Physicians working in jails and prisons can obtain a license to prescribe buprenorphine 3. Jails and prisons can obtain a license for an opioid treatment program 4. Jails and prisons can obtain state and federal licenses for health care services.
65 Why?
66 It s the right thing to do
67 When?
68 Now
69 How?
70 Leadership
71 The Governor
72 The Legislature
73 Counties
74 NYSAM
75 NYSAM 1. Create a position statement that establishes a single standard for treatment of opioid use disorders whether in corrections or the community.
76 NYSAM 1. Create a position statement that establishes a single standard for treatment of opioid use disorders whether in corrections or the community. 2. Advocate Albany to mandate use of medication-assisted treatment within corrections in NYS.
77 NYSAM 1. Create a position statement that establishes a single standard for treatment of opioid use disorders whether in corrections or the community. 2. Advocate Albany to mandate use of medication-assisted treatment within corrections in NYS. 3. Advocate for mandatory accreditation of health services including substance abuse treatment within jails and prisons.
78 Thank-you
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism
Treatment for Addiction in the Community Reduces Drug Use, Crime and Recidivism Richard A. Rawson, Ph.D, Professor Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act
IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This
Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:
Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society
Using Drugs to Treat Drug Addiction How it works and why it makes sense
Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic
John R. Kasich, Governor Orman Hall, Director
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
How To Treat An Addictive Disorder In Criminal Justice
Medication Assisted Treatment For Opiate Addiction in Correctional Settings Jeff Baxter, MD Dept. of Family Medicine UMASS Medical School Joshua Lee, MD, MS Dept. of General Internal Medicine New York
Opioid/Opiate Dependent Pregnant Women
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation
Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction
Frequently Asked Questions (FAQ s): Medication-Assisted Treatment for Opiate Addiction March 3, 2008 By: David Rinaldo, Ph.D., Managing Partner, The Avisa Group In this FAQ What medications are currently
Opioid Addiction & Corrections
Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and
Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis
The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
EPIDEMIOLOGY OF OPIATE USE
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months
Impact of Systematic Review on Health Services: The US Experience
Impact of Systematic Review on Health Services: The US Experience Walter Ling MD Integrated Substance Abuse Programs (ISAP) UCLA The effectiveness of interventions for addictions: The Drug and Alcohol
Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment
Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics
The Need for Medication-Assisted Treatment (MAT)
Presenters Erin Hall MSOT Hon. Kyle B. Haskins Closed Doors or Welcome Mat? Opening the Way for Medication-Assisted Treatment in Family Drug Courts Oklahoma Specialty Court Conference Thursday September
Testimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
BUPRENORPHINE TREATMENT
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West
Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015
Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid
Opioid overdose can occur when a patient misunderstands the directions
Facts About Opioid Overdose How Does an Overdose Occur? Opioid overdose can occur when a patient misunderstands the directions for use, accidentally takes an extra dose, or deliberately misuses a prescription
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
Ohio Legislative Service Commission
Ohio Legislative Service Commission Bill Analysis Brian D. Malachowsky H.B. 378 130th General Assembly () Reps. Smith and Sprague BILL SUMMARY Prohibits a physician from prescribing or personally furnishing
Care Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call
Opioid Treatment Programs at the Baltimore City Detention Center
Opioid Treatment Programs at the Baltimore City Detention Center Greg Warren, MA, MBA Director of Substance Abuse Services Maryland Department of Public Safety and Correctional Services OTP Interventions
Questions to ask before going to rehab by Rehab-Programs.org 2011
Table of Contents Questions to Ask Before Going to Rehab... 1 Do I really need to check into an inpatient drug rehab center?... 2 How long will I stay in the rehab center?... 2 What is the track record
Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia
Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE
Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011
Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids
Practice Protocol. Buprenorphine Guidance Protocol
Practice Protocol Buprenorphine Guidance Protocol Developed by the Arizona Department of Health Services Division of Behavioral Health Services Effective Date: 02/23/11 Title Buprenorphine Guidance Protocol
Hampden County Sheriff s Department. Special Commission on Substance Abuse Addiction Treatment in the Criminal Justice System March 20, 2015
Hampden County Sheriff s Department Special Commission on Substance Abuse Addiction Treatment in the Criminal Justice System March 20, 2015 2 Who are these offenders? 3 In Hampden County 87% are male 40%
VI. Substance Use Disorder Services
VI. Substance Use Disorder Services Background In Pennsylvania, administration of services for persons with substance use disorders (SUD) is shared by the Bureau of Drug and Alcohol Programs (BDAP) in
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings
Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,
Resources for the Prevention and Treatment of Substance Use Disorders
Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug
Washington State Interagency Opioid Working Plan
Washington State Interagency Opioid Working Plan INTRODUCTION January 2016 Washington State is currently experiencing an opioid abuse and overdose crisis involving prescription opioids and heroin. Approximately
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section
The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section TITLE I: PREVENTION SUBTITLE A- PRESCRIBER EDUCATION PRACTITIONER EDUCATION This subtitle requires practitioners who
One example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
Medication-Assisted Addiction Treatment
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
Commission on Criminal Justice and Sentencing Reform. Wednesday, June 3 rd, 2015 1:00pm to 5:00pm
Treatment Capacity in Illinois Commission on Criminal Justice and Sentencing Reform Wednesday, June 3 rd, 2015 1:00pm to 5:00pm Introduction What is the treatment capacity in Illinois? For mental health?
Naloxone: Overview, Criminal Justice and other Special Settings
Naloxone: Overview, Criminal Justice and other Special Settings Ingrid Binswanger, MD, MPH, MS Division of General Internal Medicine Affiliated Member, Division of Substance Dependence University of Colorado
Medication treatments for opioid use disorders
Medication treatments for opioid use disorders Summary for counties JUDITH MARTIN, Medical Director of Substance Use Services, San Francisco Department of Public Health Brief history of Methadone and Buprenorphine
How To Treat Anorexic Addiction With Medication Assisted Treatment
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
Heroin Overdose Trends and Treatment Options. Neil A. Capretto, D.O., F.A.S.A.M. Medical Director
Heroin Overdose Trends and Treatment Options Neil A. Capretto, D.O., F.A.S.A.M. Medical Director Type date here www.gatewayrehab.org Drug Overdose Deaths Increasing in Allegheny County Roberta Lojak holds
Treatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
Web-Based Resources. Locating Treatment
Web-Based Resources Locating Treatment http://dpt2.samhsa.gov/treatment/ -- This is the Substance Abuse and Mental Health Services Administration s (SAMHSA) page for locating both public and private opiate
Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse
Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine
Alcoholism and Substance Abuse
State of Illinois Department of Human Services Division of Alcoholism and Substance Abuse OVERVIEW The Illinois Department of Human Services, Division of Alcoholism and Substance Abuse (IDHS/DASA) is the
Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course
The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,
ALAMEDA COUNTY SUBSTANCE USE DISORDER (SUD) SERVICES
ALAMEDA COUNTY SUBSTANCE USE DISORDER (SUD) SERVICES Current Configuration and Vision for the Future Presentation to Board of Supervisors Health Committee March 23, 2015 1 Presentation Overview Demographic
The National Community Detoxification Pilot
The National Community Detoxification Pilot Aoife Dermody, Progression Routes Initiative NDCI, 2011 Community Detoxification Protocols Guidelines for outpatient detoxification from methadone or benzodiazepines
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
Testimony on Addressing Heroin and Opioid Addiction. Theodore Dallas. Secretary, Department of Human Services. Center for Rural Pennsylvania
Testimony on Addressing Heroin and Opioid Addiction Theodore Dallas Secretary, Department of Human Services Center for Rural Pennsylvania July 29, 2015 1 P a g e Introduction Good morning Senator Yaw,
Role of Medication in the Treatment of Opioid Use Disorders
Role of Medication in the Treatment of Opioid Use Disorders Carolyn Baird, DNP, MBA, RN-BC, CARN-AP, CCDPD, FIAAN International Nurses Society on Addictions (IntNSA) August 24, 2015 Disclosures Carolyn
Discontinuation: Involuntary Discharge
Discontinuation: Involuntary Discharge TYPICALLY A PROCESS NOT AN EVENT Objectives 2 Review indications for discharge. Develop a therapeutic approach, in the context of the nature of Substance Use Disorders.
Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts
Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Educational Objectives: Review epidemiology of opioid addiction in
Opioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
Current Model of Drug Care. Components of a Full Drug Care Service
Current Model of Drug Care Treatment Detox Rehab Components of a Full Drug Care Service (1) (2) (3) (4) (5) (6) (7) (8) (9) Community Preparation Treatment Detox Rehab Community Community Prison work Halfway
National Perspectives in Medication Assisted Treatment
National Perspectives in Medication Assisted Treatment Addiction Medicine Asheville March 21,2014 Melinda Campopiano, MD Medical Officer Substance Abuse & Mental Health Services Administration Guten Appetit
POLICY AND PROCEDURES FOR PROVIDING NARCOTIC ADDICTION TREATMENT TO PREGNANT OPIOID DEPENDENT INMATES INCARCERATED IN THE COUNTY JAIL
PURPOSE POLICY AND PROCEDURES FOR PROVIDING NARCOTIC ADDICTION TREATMENT TO PREGNANT OPIOID DEPENDENT INMATES INCARCERATED IN THE COUNTY JAIL To outline the procedures used in recognizing and providing
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the
The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence
M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen
Medication-Assisted Treatment for Opioid Addiction
Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid
DrugFacts: Treatment Approaches for Drug Addiction
DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please
Beyond SBIRT: Integrating Addiction Medicine into Primary Care
Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison
Medications for Alcohol and Drug Dependence Treatment
Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram
Advances in Addiction Science and Treatment. Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014
Advances in Addiction Science and Treatment Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014 Treatment Research Research Institute, Institute, 20132012 Presentation 1. What is driving
Licensure of Substance Abuse Treatment Programs Required Amendments
Licensure of Substance Abuse Treatment Programs Required Amendments Public Health Council August 12, 2015 Jim Cremer, Deputy Director Erica Piedade, Director of Quality Assurance & Licensing, Overview
ONDCP. Drug Policy Information Clearinghouse FACT SHEET John P. Walters, Director www.whitehousedrugpolicy.gov 1-800-666-3332
UNUM Executive Office of the President Office of National Drug Control Policy E PLURIBUS OFFICE OF NATIONAL POLICY D RUG CONTROL ONDCP March 2001 Drug Policy Information Clearinghouse FACT SHEET John P.
TESTIMONY. March 17, 2014. Rutland, VT
Community Solutions to Breaking the Cycle of Heroin & Opioid Addiction TESTIMONY Harry Chen, MD, Commissioner of Health March 17, 2014 Senate Committee on the Judiciary Franklin Conference Center at the
Putting Addiction Treatment Medications to Use: Lessons Learned
Putting Addiction Treatment Medications to Use: Lessons Learned George E. Woody, M.D. Laura McNicholas, M.D., Ph.D. Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia
World Health Organization
myths and facts for policy makers responsible for substance dependence prevention, treatment and support programs World Health Organization Myth 1. Drug dependence is simply a failure of will or of strength
Office-based Treatment of Opioid Dependence with Buprenorphine
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
PATHWAYS TO RECOVERY
PATHWAYS TO RECOVERY PATHWAYS TO RECOVERY When Faces & Voices of Recovery was launched in 2001, our founding goal was to celebrate and honor recovery in all of its diversity. We believe that everyone has
Guidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION
1145 W. Diversey Pkwy. 773-880-1460 Chicago, Illinois 60614 www.ncchc.org Guidance for Disease Management in Correctional Settings OPIOID DETOXIFICATION NCCHC issues guidance to assist correctional health
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
BUPRENORPHINE TREATMENT
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment Act of 2000 (DATA 2000) Developed by Mountain West
Sweeping Heroin Bill Presents Challenges for All Involved
Sweeping Heroin Bill Presents Challenges for All Involved A heroin bill was identified by both parties, both chambers, and the Governor as Must Pass legislation in 2015. Unfortunately, the parties and
Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to
2012 Page 1 of 6 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:
ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15
ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;/13;06/14;07/15 WRITTEN BY Jim Johnson Page 1 REVISED BY AUTHORIZED BY Jessica Moeller Debra Johnson I. APPLICATION: THUMB
U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health
TESTIMONY of the American Medical Association before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Re: Examining Legislative Proposals to Combat our Nation's
Table of Contents. I. Introduction... 2. II. Summary... 3. A. Total Drug Intoxication Deaths... 5. B. Opioid-Related Deaths... 9
Table of Contents I. Introduction... 2 II. Summary... 3 III. Charts A. Total Drug Intoxication Deaths... 5 B. Opioid-Related Deaths... 9 C. Heroin-Related Deaths... 11 D. Prescription Opioid-Related Deaths...
Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Substance Use Disorder Treatment in Los Angeles: The Past, Present, and Future
Substance Use Disorder Treatment in Los Angeles: The Past, Present, and Future Michael Ballue, CADC II, BSBA Chief Strategy Officer Behavioral Health Services Gary Tsai, MD Medical Director & Science Officer
Buprenorphine Therapy in Addiction Treatment
Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition
Use of Buprenorphine in the Treatment of Opioid Addiction
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
Minnesota County Attorneys Association Policy Positions on Drug Control and Enforcement
T H E M I N N E S O T A C O U N T Y A T T O R N E Y S A S S O C I A T I O N Minnesota County Attorneys Association Policy Positions on Drug Control and Enforcement Adopted: September 17, 2004 Introduction
Heroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to
2012 Page 1 of 8 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:
Evidence Based Practice in the Treatment of Addiction Treatment of Addiction. Steve Hanson
Evidence Based Practice in the Treatment of Addiction Treatment of Addiction Steve Hanson History of Addiction Treatment Incarceration Medical Techniques Asylums What We Learned These didn t work Needed
Congressional Testimony. Laurence M. Westreich, M.D. President, American Academy of Addiction Psychiatry
Congressional Testimony Laurence M. Westreich, M.D. President, American Academy of Addiction Psychiatry Combatting the Opioid Abuse Epidemic: Professional and Academic Perspectives, April 23 rd 2015 Subcommittee
Various therapies are used in the
National Survey of Substance Abuse Treatment Services The N-SSATS Report January 28, 2010 Overview of Opioid Treatment Programs within the United States: 2008 In Brief In 2008, a total of 1,132 (8 of all
TREATMENT MODALITIES. May, 2013
TREATMENT MODALITIES May, 2013 Treatment Modalities New York State Office of Alcoholism and Substance Abuse Services (NYS OASAS) regulates the addiction treatment modalities offered in New York State.
Federal Response to Opioid Abuse Epidemic
Healthcare Committee Federal Response to Opioid Abuse Epidemic On May 1, 20215 the Energy and Commerce Subcommittee on Oversight and Investigations held a hearing entitled What is the Federal Government
A Drug Policy for the 21st Century. Office of National Drug Control Policy
A Drug Policy for the 21st Century October 18, 2014 International Nurses Society on Addictions Health Care Reform & Its Impact on Addictions Nursing: Navigating Change through the Rapids David K. Mineta,
MEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy
Patients are still addicted Buprenorphine is simply a substitute for heroin or
BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module VI: Myths About the Use of Medication in Recovery Patients are still addicted Buprenorphine is simply a substitute
Medication Assisted Treatment
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice